Iterion Therapeutics Information
Contact top employees from
Iterion Therapeutics
Summary
Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent first-in-cla...Show more
Industries
Biotechnology
Headquarters Location
Employees Size
10-50 employees
Founded
2014
Competitors
Founded | Type | Employees | Revenue | Funding | |
|---|---|---|---|---|---|
| 2018 | Privately Held | 25 - 100 | 2.5M | $113.8M | |
| 2018 | Privately Held | 25 - 100 | < 1M | $74M | |
| 2018 | Privately Held | 100-200 | < 1M | $0 | |
| 2011 | - | 500-1000 | - | $- | |
| 2014 | - | 100-200 | - | $- |
Employees Turnover 3 quarter 2025
Number of employees switched from or switched to
Total number all of employee turnover
Length of Employment
Employee tenure at Iterion Therapeutics shows a diverse range of experience levels:
9% have been with the company for less than 1 year27% for 1–2 years18% for 3–4 years27% for 5–7 years9% for 8–10 years9% have over 11 years of service at Iterion TherapeuticsEx-employees positions
In Company
In New Company
Contact top employees from
Iterion Therapeutics
Rahul Aras
President & CEO
Elena Ramirez
Sr. Scientist
Prashi Jain
Director, Drug Discovery
Aundrietta Duncan
Sr. Director, Research and Non-clinical Development
Stephen Horrigan
Chief Scientific Officer
Gowri Sukumar
Senior Director CMC And Regulatory Affairs
Laura Mendez
HR & Operations Manager
Snehapriya
CMC & Regulatory Affairs Specialist
Maha Youssefi
Associate Researcher
Janet Julissa Simmons
Senior Research Associate
Similar Companies
FAQ
Iterion Therapeutics operates in the Biotechnology industries. More details can be found on the official website: iteriontherapeutics.com.
The headquarters of Iterion Therapeutics are located in Houston, United States.
Iterion Therapeutics currently employs 10-50 people.
Well-known competitors of Iterion Therapeutics include Cedilla Therapeutics, Nutcracker Therapeutics, Aviceda Therapeutics and Aimmune Therapeutics.
